Skip to main content

Articles By Jack Cush, MD

psoriatic.PIP_.JPG

Upadacitinib Clinical Efficacy in Psoriatic Arthritis

By Jack Cush, MD
01 April 2021

McInnes and colleagues have published the results of the SELECT - PsA trial in NEJM showing updacitinib (UPA) to be superior to placebo in active psoriatic arthritis (PsA) patients, with 15 mg UPA equal to adalimumab (ADA) and 30 mg UPA qd being superior to ADA.

Read Article
heart-attack.jpg

Inflammatory Conditions Up the Risk of Premature Myocardial Infarction

By Jack Cush, MD
31 March 2021

The European Journal of Preventive Cardiology reports that younger patients with their first myocardial infarction before age 50 yrs have a higher risk of having a systemic inflammatory disease (SIDs) and higher rates all-cause mortality.

Read Article
Fracture.spine_.op_.jpg (keep)

Aortic Calcification and Lumbar Fracture Risk in Older Men

By Jack Cush, MD
30 March 2021

Fractures of the spine and abdominal aortic calcification (AAC) can both be visualized with spinal imaging; a new report shows that finding both radiographic vertebral fracture and AAC on the same lateral spine images may predict the risk of future incident major osteoporotic fracture in older me

Read Article
BP

Hypertension Unaffected by Urate Lowering Therapy

By Jack Cush, MD
30 March 2021

Does uric acid contribute to the risk of hypertension (HTN)?  A recent cohort trial shows that allopurinol in young adults does not sufficiently lower blood pressure (BP).

Read Article
RheumNow Podcast square

RheumNow Podcast – Infection in ANCA-Associated Vasculitis (3.26.2021)

By Jack Cush, MD
26 March 2021

Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on RheumNow.com.

Read Article
FDA.Not_.jpg

FDA Panel Rejects Tanezumab for Osteoarthritis

By Jack Cush, MD
25 March 2021

A two day FDA review by the Drug Safety and Risk Management and Arthritis Advisory Committees has yielded a 19-1 vote against the approval of tanezumab, a nerve growth factor inhibitor, for use in osteoarthritis (OA).

Read Article
pregnant.baby_.hands_.jpg

Safety of Paternal DMARD or Biologic Use

By Jack Cush, MD
22 March 2021

A large cohort study of expectant fathers treated for immune-mediated inflammatory diseases (IMIDs) failed to show any detrimental effect from paternal exposure to immunosuppressive or biologic agents on offspring outcomes.

Read Article
gout.tophi_.jpg

RECIPE Trial - Mycophenolate to Suppress Immunogenicity with Pegloticase in Gout

By Jack Cush, MD
22 March 2021

Pegloticase is indicated in the treatment of severe gout patients but prolonged use may be limited by immunogenicity to the PEG moiety. A randomized, controlled trial has shown that concomitant mycophenolate mofetil (MMF) may prolong the efficacy of pegloticase in gout.

Read Article
RA ILD RTX lung

Rituximab vs. JAK inhibitors in Rheumatoid Lung Disease

By Jack Cush, MD
19 March 2021

There are no current FDA approved therapies for rheumatoid arthritis associated interstitial lung disease (RA-ILD) or bronchiectasis, but a recent retrospective cohort study showed equivalent outcomes when RA-ILD patients were treated with either rituximab or janus kinase inhibitors.

Read Article
RheumNow Podcast square

RheumNow Podcast – Great Associations (3.19.2021)

By Jack Cush, MD
18 March 2021

Dr. Jack Cush rants on the journal reports, news and FDA actions featured this past week on RheumNow.com.

Read Article
×